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A world without vaccine-preventable disease, disability,  
and death
Mission Statement
To protect the health of Americans and global citizens by 
preventing disease, disability, and death through immunization
Purpose
The purpose of this strategic framework is to articulate  
CDC’s goals, objectives, and strategies for effectively meeting 
global immunization challenges during 2011–2015. This 
document is intended to build on and complement CDC’s 
previous 5-year plan: CDC GLOBAL IMMUNIZATION 
STRATEGIC FRAMEWORK, 2006–20101 and is linked to the 
2010 National Vaccine Plan of the U.S. Department of Health  
and Human Services2.




The burden of vaccine-preventable diseases (VPDs) in the 
United States has been greatly reduced due to childhood 
immunization. However, even as VPDs such as polio, measles, 
and rubella have been eliminated in this country, the United 
States remains vulnerable to disease importations as long as 
they persist elsewhere. In an era of mass travel and global 
epidemics, the health of U.S. citizens is closely related to disease 
occurrence in other countries. Thus, support for immunization 
programs worldwide contributes toward providing an “umbrella 
of protection” for the United States, as well as fulfilling the U.S. 
government’s broader commitment to global health.
Childhood immunization is one of the most cost-effective 
public health interventions. Basic immunizations are estimated 
to prevent more than 2.5 million annual child deaths globally, 
primarily due to prevention of measles, pertussis, and tetanus. 
Vaccines also prevent severe morbidity from other devastating 
diseases such as polio for millions more children. Vaccination 
of children also is expected to avert adult deaths by preventing 
hepatitis B virus (HBV)-related cirrhosis and liver cancer and 
human papillomavirus (HPV)-related cervical cancer. However, 
immunization can potentially do much more. The World Health 
Organization has estimated that about 1.5 million children under 
age 5 years continue to die annually from VPDs (approximately 
20% of overall childhood mortality). In particular, pneumococcal 
conjugate vaccine (PCV), Haemophilus influenzae type B (Hib) 
vaccine, and rotavirus vaccine prevent pneumonia and diarrhea, 
the two leading causes of death among children under age 5 years 
in the developing world; the expanded use of these vaccines will 
be critical for achieving UN Millennium Goal 4—to reduce 1990 
child mortality levels by two-thirds by 2015. 
An estimated 130 million infants are born around the world each 
year. Protecting each new birth cohort from VPDs requires a 
well-functioning and accessible immunization service delivery 
system as a cornerstone of national public health systems. 
Routine immunization service delivery at fixed posts or through 
periodic outreach activities (e.g., child health days, immunization 
weeks) provides at least three contacts per year to more than 100 
million infants and their caretakers. In addition, supplemental 
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immunization campaigns play key roles in making progress 
toward meeting targeted disease control goals such as polio 
eradication and measles mortality reduction. However, these 
achievements are temporal because large outbreaks are probable, 
and cases and deaths are likely to increase, without further 
improvements in immunization service delivery.   
As a well-accepted and demanded community health program, 
the immunization service delivery platform is key in ensuring 
equitable distribution of other essential health services and 
decreasing morbidity and mortality from other diseases. 
Through either routine immunization services or supplemental 
immunization campaigns, immunization service delivery is the 
backbone upon which multiple additional services are added, 
including delivery of de-worming medicine, vitamin A, long-
lasting insecticide-treated bed nets, safe water systems, and other 
health commodities. Also, the infant immunization contact 
provides opportunities to screen mothers for HIV/AIDS and 
provide health education on a variety of topics. The integrated 
service delivery process must be coordinated and rational so 
that health care workers are not overburdened. However, if done 
effectively, integrated service delivery offers the potential to 
efficiently expand outreach for multiple health care services to 
previously unreached populations. 
Strategic Principles
This immunization framework is based on key elements of CDC’s 
overall global health strategy:
•  Assist ministries of health in planning and managing health 
programs effectively.
•  Eradicate and eliminate disease where possible and feasible.
•  Strengthen the ability of governments and multilateral 
organizations to achieve major global health goals.
•  Create a flexible and responsive portfolio of global health 
programs at CDC to reflect the changing burden and 
distribution of disease globally.
•  Acquire new knowledge to improve achievement of global 
health goals. 
•  Improve the effectiveness and efficiency of health systems 
globally. 
•  Promote equal access and equitable delivery to all people of 
needed vaccines and other health interventions.  
Progress, Aims, and Challenges
Although progress was made during 2006–2010 in reducing 
global morbidity and mortality from VPDs, key overarching 
aims and challenges in global immunization remain for CDC to 
address during 2011–2015. 
Polio: Since the Global Polio Eradication Initiative (GPEI) 
began in 1988, the number of polio cases around the world 
has fallen by more than 99%, from more than 350,000 cases 
that year to 1979 cases in 2005 and to fewer than 1300 cases in 
2010. Transmission of wild poliovirus (WPV) type 2 has been 
eliminated since 1999, and indigenous transmission of WPV 
types 1 (WPV1) and 3 (WPV3) has been eliminated from all 
but four countries (Afghanistan, India, Nigeria, and Pakistan) 
since 2005. However, progress slowed since 2005, with ongoing 
WPV1 and WPV3 transmission in all endemic countries and the 
re-establishment of transmission in four previously polio-free 
countries (Angola, Chad, Democratic Republic of the Congo, and 
Sudan). This led to the development of a new GPEI strategic plan 
for 2010–2012, which incorporates lessons learned and introduces 
specific new strategies, milestones for monitoring progress, and 
1 2
enhanced oversight mechanisms for taking corrective actions. 
The objectives are to interrupt WPV transmission by the end of 
2012 and to certify global polio eradication by the end of 2015. 
CDC has been a key partner in the GPEI since 1988, providing 
critical technical and financial support for polio immunization 
activities to interrupt WPV transmission, maintain and enhance 
laboratory surveillance for polioviruses, monitor progress toward 
reaching epidemiological targets, and support development and 
implementation of a polio eradication research agenda with the 
long-term aim of stopping all global use of oral polio vaccine.
Measles and rubella: Endemic measles and rubella have been 
eliminated from the Western Hemisphere. To sustain and build 
on this achievement, CDC is working to control and eliminate 
measles and rubella in parts of the world responsible for disease 
importations into the United States. CDC is a founding member 
of the Measles Initiative, which has helped cut measles deaths 
globally by 78%, down from an estimated 733,000 deaths in 2000 
to 345,000 deaths in 2005 and to 164,000 deaths in 2008. This 
decline played a major role in overall declines in child mortality 
during the past decade. However, gains in reducing measles 
mortality are fragile. Since 2009, more than 30 African countries 
have experienced measles outbreaks resulting from gaps in routine 
measles vaccination coverage and a failure to continue with 
timely, high-quality follow-up measles campaigns. Substantial 
ongoing technical and financial support will be required to attain 
and sustain further mortality reduction and to reach regional 
elimination goals that have the potential to eventually result in 
measles eradication. Measles-related efforts are closely linked with 
efforts to increase use of rubella-containing vaccines to prevent 
congenital rubella syndrome, which affects an estimated 110,000 
infants born each year in developing countries, and to monitor 
progress  toward achieving and maintaining rubella control and 
elimination goals.
Hepatitis B: In the United States, use of hepatitis B vaccine 
(HepB) in childhood immunization programs has decreased 
hepatitis B incidence more than 90%; however, approximately 
40,000 immigrants with chronic hepatitis B virus (HBV) infection 
are admitted each year to the United States from other countries. 
Globally, chronic HBV infections cause an estimated 620,000 
deaths annually from cirrhosis and liver cancer. CDC provides 
technical assistance designed to increase the number of countries 
using HepB in childhood immunization programs, including 
use of a birth dose to prevent HBV transmission from mother 
to infant and ultimately reduce the burden of chronic HBV 
infections among immigrants in the United States. In addition, 
CDC provides technical assistance to WHO regions and countries 
on monitoring progress toward achieving hepatitis B control goals. 
Maternal and neonatal tetanus: Maternal and neonatal tetanus 
(MNT) was eliminated in the United States. Substantial progress 
has been made toward achieving the MNT elimination goal 
globally, and neonatal tetanus (NNT) deaths declined from 
approximately 787,000 in 1988 to 59,000 in 2008. However, as 
of 2010, 40 countries had yet to achieve MNT elimination in all 
districts. CDC provides technical assistance to many of these 
countries on improving tetanus immunization of pregnant 
women, maintaining and strengthening tetanus surveillance, and 
conducting country assessments to validate tetanus elimination.
Routine immunization: The WHO/UNICEF Global 
Immunization Vision and Strategy, 2006–2015 (GIVS)3 provides 
guidance to countries in strengthening routine immunization 
programs and vaccinating more people. GIVS aims to achieve 
90% national 3-dose diphtheria-tetanus-pertussis vaccine (DTP3) 
coverage by age 12 months in all countries and 80% coverage 
in every district or equivalent administrative unit by 2010, and 
to sustain these levels through 2015. Estimated global DTP3 
coverage in the 193 WHO member states increased from 74% 
in 2000 to 78% in 2005 and to 82% in 2009; DTP3 coverage in 
2009 reflects vaccination of 107.1 million infants with three doses 
of DTP vaccine (14.6 million more than in 2000). However, an 
estimated 23.2 million children worldwide—almost 20% of the 
children born each year—did not receive three doses of DTP 
vaccine during the first year of life in 2009; 70% of these infants 
live in 10 countries, with approximately half in India (37%) and 
Nigeria (14%). A recent review of published literature found that 
immunization program weakness was the leading reason that 
children did not complete the 3-dose DTP vaccination series.
3  http://www.who.int/vaccines-documents/DocsPDF05/GIVS_Final_EN.pdf
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VPD surveillance and information systems: Well-functioning 
laboratory-based VPD surveillance systems and VPD information 
systems are critical for managing, monitoring, and evaluating 
immunization programs and assessing program impact on VPD 
disease burden. CDC provides technical and financial support 
to multiple global VPD surveillance and laboratory networks, 
including the Global Polio Laboratory Network, the Global 
Measles and Rubella Laboratory Network, the Global Influenza 
Surveillance Network, the Global Rotavirus Surveillance Network, 
and the Global Invasive Bacterial Disease Surveillance Network, 
as well as regional surveillance and laboratory networks for 
yellow fever (PAHO, AFRO), Japanese encephalitis (SEARO), 
and pediatric bacterial meningitis (AFRO). CDC also provides 
technical and operational research support to strengthen the 
quality and use of data from VPD surveillance and information 
systems. 
New and underused vaccines: Despite the extraordinary progress 
made in reducing VPD morbidity and mortality during the past 
decade, the immunization agenda is unfinished. CDC actively 
supports the evaluation and introduction of available and 
underused vaccines—Hib, PCV, rotavirus, HPV, meningococcal 
group A, HepB birth dose, rubella, Japanese encephalitis, typhoid, 
cholera, and yellow fever—which have the potential to greatly 
reduce global VPD morbidity and mortality. CDC also actively 
supports research to develop new vaccines to protect against 
leading killers in developing countries (e.g., HIV, malaria, 
tuberculosis).  
The time is now optimal to accelerate the introduction of Hib, 
PCV, and rotavirus vaccines, which can reduce the 2.9 million 
annual deaths due to pneumonia and diarrhea among children 
under age 5 years by 40%–60%. WHO has recommended 
introduction of these vaccines in childhood immunization 
programs in all countries, and the GAVI Alliance (GAVI) is 
committed to provide funding support for their introduction in 
the poorest countries. As of December 2010, Hib vaccine has been 
introduced in 171 countries, rotavirus vaccine in 26 countries, 
and PCV in 58 countries. HPV vaccine, which prevents cervical 
cancer caused by HPV, has been introduced in 31 countries. A 
new meningococcal group A vaccine was introduced in Burkina 
Faso in 2010. Plans are underway to introduce the vaccine in 
25 African countries to eliminate epidemics of meningitis and 
prevent up to 123,000 deaths and 237,000 cases of disability in the 
Africa meningitis belt within 10 years. 
Widespread introduction of new and underused vaccines still 
depends on addressing key challenges, including inadequate 
vaccine supply, low immunization system capacity, creation of 
sustainable partnerships to maximize synergy in reaching global 
goals, and high cost of newer vaccines. In addition, although 
WHO has recommended that countries introduce new and 
underused vaccines, public health officials in each country 
must make their own decisions based on national priorities 
and capacity. To facilitate country decision-making processes, 
CDC provides direct technical assistance on evaluating the 
disease burden, developing surveillance capacity, performing 
economic analysis, and understanding program implications and 
vaccine impact, and indirect assistance through participation in 
partnerships including GAVI and the GAVI-funded Accelerated 
Vaccine Initiative. CDC also provides technical support on the 
development of national immunization technical advisory groups.
U.S. Government and Global Health Context
Although CDC is committed to targeted efforts to strengthen 
immunization systems and achieve time-bound impacts on 
VPDs, these aims must be implemented in the context of 
other global public health programs in collaboration with U.S. 
Government (USG) and other partners. 
Global Health Initiative (GHI)4: The USG launched this new 
6-year (FY 2009–FY 2014) initiative in May 2009 to focus 
attention on broader global health challenges—maternal and 
child health, family planning, and neglected tropical diseases—
while maintaining robust funding for and strong commitment 
to the fight against high-profile communicable diseases such as 
HIV/AIDS. The GHI also emphasizes the need to adopt a more 
integrated approach to improving health and strengthening health 
systems. Immunization remains a cornerstone program within 
GHI, especially in the target area of maternal and child health. 
CDC’s immunization strategies will reinforce the GHI principles 
and emphasize the importance of linking closely with other USG 
agency health programs at the country level. 
4  http://www.theglobalhealthinitiative.org/
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2010  National Vaccine Plan (NVP)5: The 2010 National Vaccine 
Plan developed by the U.S. Department of Health and Human 
Services (HHS) lays out key strategies and objectives for 2011–
2020. Although it focuses primarily on domestic issues, the NVP 
includes a specific goal area on global immunization in recognition 
of the close synergies between USG and international programs. 
This goal area includes objectives for all HHS agencies and 
provides a broad framework for potential contributions by U.S. 
academic and other relevant partners to global efforts. The CDC 
Global Immunization Strategic Framework 2011–2015 contributes 
to the NVP and is consistent with the overall HHS plan. 
Decade of Vaccines (DOV)6: Spurred by the Bill and Melinda 
Gates Foundation’s January 2010 commitment of $10 billion 
over 10 years for global immunization, WHO, UNICEF, and 
other global immunization partners have called for a Decade 
of Vaccines (2011–2020). This effort is designed to build on the 
achievements of the GIVS and scale up previous strategic targets. 
Key components of the DOV will be strengthening public support 
for vaccine use and financing, expanding the reach of delivery 
programs, maintaining a strong pipeline for vaccine research 
and development, and exploring strategies that can ensure global 
access to sufficient supplies of affordable vaccines. CDC is a key 
contributor to developing the DOV strategic document and 
global plan of action.  
5  http://www.hhs.gov/nvpo/vacc_plan/2010%20Plan/nationalvaccineplan.pdf 
6  http://www.who.int/immunization/newsroom/press/news_release_decade_vaccines/en/
Framework Format
CDC is committed to work with global partners toward achieving 
six overarching goals proposed in the framework during the next 
5 years: 
Goal 1:   Control, eliminate, or eradicate targeted VPD disability 
and death globally (NVP Goal 5/Objective 5.2)
Goal 2:  Strengthen capacity and enhance performance of health 
systems to sustainably deliver routine immunization 
services (NVP Goal 5/Objective 5.2)
Goal 3:  Strengthen VPD health information and surveillance 
systems to enhance decision-making capacity for 
immunization programs (NVP Goal 5/Objective 5.1)
Goal 4:  Increase the appropriate development, introduction, 
and use of new and underutilized vaccines (e.g., Hib, 
pneumococcal, rotavirus, HPV, MenA, HepB birth 
dose, rubella, JE , cholera, typhoid, malaria, yellow 
fever) to prevent diseases of global and regional public 
health importance (NVP Goal 5/Objective 5.3)
Goal 5:  Promote synergies between immunization and other 
public health interventions to strengthen health 
systems and contribute to decreased maternal and child 
mortality and morbidity (NVP Goal 5/Objective 5.2)
Goal 6:  Build and strengthen partnerships that maximize 
coordination and synergy in meeting immunization 
goals (NVP Goal 5/Objective 5.6)
Specific objectives provide realistic targets that measure the 
accomplishment of each goal. To help monitor progress over time, 
every objective also includes at least one key measure of success. 
Achievement of these goals and objectives will require inputs by 
multiple partners, national governments, and CDC. The strategies 
articulated in the framework outline broad activity areas where 
CDC can make specific contributions.  

Goal 1 
Control, eliminate, or eradicate targeted VPD disability and 
death globally (NVP Goal 5/Objective 5.2)
Objectives
1. Achieve, certify, and maintain polio eradication 
Key measures of success:  
Cessation of all wild poliovirus transmission by end 2012  
Certification of global polio eradication by end 2015
Strategies:
 i.  Conduct technical assessment and epidemiologic analysis to 
monitor the progress in reaching global eradication goals outlined 
in the Strategic Plan for Global Polio Eradication 2010–2012.1
 ii.  Provide technical and financial support for supplemental 
immunization activities to interrupt indigenous and re-
established poliovirus transmission, limit international spread, 
and stop new outbreaks. 
 iii.  Provide technical and financial support to maintain and 
enhance epidemiologic and laboratory-based surveillance for 
polioviruses and integrate with surveillance for other VPDs 
and communicable diseases as appropriate. (See also Goal 3, 
Objectives 1 and 2.)
 iv.  Contribute to the development and implementation of a research 
agenda to accelerate polio eradication, identify and evaluate new 
immunization and surveillance strategies, and identify safeguards 
to minimize poliovirus risks in the post-eradication period.
2. Decrease global measles mortality and morbidity
Key measure of success:  
By 2015, reduce estimated global measles mortality by 95% or 
more in comparison with 2000
Strategies:
 i.  Provide technical and financial support to achieve and sustain 
measles mortality reduction and elimination goals by achieving 
and sustaining high 2-dose measles vaccination coverage. 
 ii.  Provide technical and financial support to maintain and enhance 
case-based, laboratory-supported measles surveillance. (See also 




iii.  Contribute to the development and implementation of a research 
agenda to strengthen the scientific basis for achieving and 
maintaining measles mortality reduction and elimination goals, 
identify optimal measles immunization and surveillance strategies, 
identify and aid in the development of new laboratory methods to 
support global measles control programs, and address scientific 
questions regarding the feasibility of measles eradication. 
3.  Accelerate global rubella control and congenital rubella 
syndrome (CRS) prevention
Key measure of success:  
By 2015, at least two of six WHO regions achieve and sustain 
rubella/CRS elimination
Strategies:
 i.  Provide technical and financial support to develop and implement 
rubella immunization plans, monitor rubella/CRS disease burden, 
and achieve and sustain control/elimination goals. 
 ii.  Provide technical and financial support to establish, maintain, 
and enhance case-based, laboratory-supported rubella and 
CRS surveillance that is appropriately integrated with measles 
surveillance when possible. (See also Goal 3, Objectives 1 and 2.)
 iii.  Contribute to the development and implementation of a research 
agenda to strengthen the scientific basis for achieving rubella 
and CRS control and elimination goals, identify optimal rubella 
immunization and surveillance strategies, and identify and aid 
in the development of new laboratory methods to support global 
rubella control programs.
4. Decrease global burden of hepatitis B
Key measure of success:  
By 2015, all countries in at least two of six WHO regions have 
reduced hepatitis B surface antigen prevalence to less than 2% 
among children under 5 years of age.
Strategies:
 i.  Provide technical assistance on developing and implementing 
hepatitis B immunization plans. 
 ii.  Provide technical assistance on developing and monitoring 
progress toward achieving hepatitis B control goals.
 iii.  Contribute to the development and implementation of a research 
agenda to identify optimal hepatitis B immunization strategies, 
strengthen the scientific basis for achieving hepatitis B control 
and elimination goals, and identify laboratory methods to 
support global hepatitis B control programs.
5. Achieve neonatal tetanus (NNT) elimination in all countries 
 Key measure of success:  
By 2015, NNT elimination (<1 case per 1000 live births in all 
districts) is achieved in all countries 
Strategies:
 i.  Provide technical assistance to countries and partners to improve 
TT coverage by strengthening routine immunization programs 
and improving the quality of supplemental immunization 
activities.
 ii.  Provide technical assistance to countries and partners to 
strengthen and maintain quality tetanus surveillance and conduct 
assessments to validate elimination. (See also Goal 3, Objectives 1 
and 2.)
6.  Decrease morbidity and mortality of other VPDs of global  
or regional importance 
 Key measure of success:  
By 2015, epidemics of serogroup A meningitis are eliminated in 
the Africa meningitis belt
Strategies:
 i.  Provide technical assistance and financial support for planning, 
implementing, and monitoring SIAs, enhancing surveillance, and 
monitoring impact and effectiveness for MenA in appropriate 
countries to prevent serogroup A meningitis outbreaks.
 ii.  Provide technical assistance and financial support for planning, 
implementing, and monitoring influenza SIAs. 
 iii.  Evaluate the impact of JE vaccination and provide technical 
assistance to strengthen JE surveillance and control programs.
 iv.  Provide technical assistance designed to strengthen pertussis 
surveillance and control programs. 
 v.  Provide technical assistance on evaluating HPV vaccine 
introduction among adolescent girls.
 vi.  Evaluate the effectiveness of implementing cholera and typhoid 
SIAs to prevent or control diarrheal disease outbreaks.

Goal 2
Strengthen capacity and enhance performance of health 
systems to sustain delivery of routine immunization services 
(NVP Goal 5/Objective 5.2)
Objectives
1.  Increase percentage of fully immunized children2 by 12 
months of age
 Key measure of success:  
By 2015, all countries achieve 90% coverage for fully immunized 
children nationally and at least 80% coverage in every district   
Strategies:
 i.  Provide technical and financial support for building and 
strengthening capacity to plan, implement, and evaluate 
immunization programs at national, regional, and global levels.
 ii.  Support countries in increasing community involvement in 
immunization services, and work with partners to identify and 
implement strategies for increasing demand for vaccines and 
addressing issues related to vaccine refusal.
 iii.  Identify, evaluate, and facilitate implementation of existing and 
new technologies that are designed to strengthen immunization 
systems and approaches to enhancing vaccine supply and 
delivery.
 iv.  Contribute to the development and implementation of a 
research agenda to strengthen the scientific basis for vaccination 
strategies to reach more children, identify populations with 
low coverage, and develop new strategies to improve coverage, 
including strengthening links between routine immunization and 
supplemental immunization activities.
2   Fully immunized child = child who has received at least BCG, HepB birthdose + Hep3, DTP3,  
OPV3, MCV1
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2.  Increase immunization coverage with appropriate 
traditional and new vaccines among older-age children  
(>1 yr), adolescents, and adults
Key measure of success:  
By 2015, all countries that routinely provide a second dose of 
measles vaccine achieve 90% 2-dose MCV coverage nationally 
and at least 80% coverage in every district
Strategies:
 i.  Develop standardized process indicators and reporting tools for 
measuring program performance in reaching children older than 
1 year of age. 
 ii.  Provide technical assistance that supports country efforts in 
defining appropriate target populations, developing policies, 
and implementing plans for vaccination of older children, 
adolescents, and adults.
 iii.  Contribute to the development and implementation of a research 
agenda to establish the scientific basis for vaccination strategies 
for reaching children beyond infancy, and conduct operations 
research to assess feasibility of implementing new vaccination 
strategies.
3.  Increase the percentage of countries with a well-functioning 
(based on WHO criteria) National Immunization Technical 
Advisory Group (NITAG) with capacity to make evidence-
based decisions on immunization policy and programs, 
including epidemiologically appropriate introduction of new 
and underused vaccines.
Key measure of success:  
By 2015, 50% of countries have a well-functioning NITAG 
Strategies:
 i.  Provide training for NITAG members and opportunities for them 
to develop appropriate knowledge and experience. 
 ii.  Partner with WHO IVB and WHO Regional Offices to provide 
balanced policy advice and information to national decision 
makers to foster priority setting on new and underused vaccines.
 iii.  Establish evidence-based mechanisms to evaluate the functioning 
of NITAGs and to gather and share country experiences on 
national decision making. 
4.  Promote safe immunization injection practices and develop 
country capacity to monitor and effectively investigate 
adverse events following immunization (AEFI)
Key measure of success:  
By 2015, 50% of middle- and lower-income countries will conduct 
a National Regulatory Assessment to guide implementation of 
post-marketing surveillance for AEFI
Strategies:
 i.  Provide technical assistance designed to introduce, evaluate, and 
improve vaccine safety monitoring and surveillance programs. 
 ii.  Provide technical assistance in responding to and evaluating 
vaccine safety signals arising from monitoring systems or other 
sources. 
 iii.  Provide technical assistance on conducting ad hoc vaccine safety 
studies to evaluate vaccine safety concerns. 
 iv.  Provide technical assistance on addressing emerging vaccine 
safety issues and communicating vaccine risks effectively and 
transparently to the public, health care providers, and other 
stakeholders. 
 v.  Provide technical assistance to countries on introducing, 
sustaining, and monitoring recommended safe injection practices 
for all vaccinations, including vaccines administered during 
routine immunization and supplemental immunization activities. 
5.  Support the development of sustainable vaccine financing 
and procurement mechanisms to maintain adequate supplies 
of vaccines at global, regional, and national levels
Key measure of success:  
By 2015, 75% of low- and low-middle income countries have a 
specific national budget line allocated to vaccine purchase and 
immunization program support
Strategies:
 i.   Provide technical assistance to regions and countries on 
developing sustainable vaccine procurement and financing 
mechanisms.
 ii.  Collaborate with partners to analyze global trends and conduct 




Strengthen VPD health information and surveillance systems 
to enhance decision-making capacity for immunization 
programs (NVP Goal 5/Objective 5.1)
Objectives
1.  Increase the number of countries with access to proficient 
laboratory networks for vaccine-preventable diseases 
Key measure of success:  
By 2015, all countries have access to a high-quality (e.g., WHO 
accredited) national or regional laboratory that can accurately 
diagnose viral and bacterial VPDs
Strategies:
 i.  Strengthen national and regional public health laboratories in 
target countries by providing the training, equipment, reagents, 
and quality control procedures needed to sustain high-quality 
diagnostics for VPDs, with the objectives of monitoring  disease 
burden, detecting outbreaks, detecting emerging variants, and 
monitoring impact of new vaccines. 
 ii.  Conduct operational research to evaluate and improve diagnostic 
and specimen-handling processes critical to functional laboratory 
networks, and to develop and introduce new diagnostic 
and specimen-handling technologies to meet evolving VPD 
surveillance needs.
 iii.  Serve as global reference laboratory for selected VPDs, and 
provide technical assistance and funding support for global and 
regional VPD laboratory network coordination. 
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2.  Increase the number of countries with VPD surveillance 
systems that meet the minimum quality criteria required for 
program impact
Key measure of success:  
By 2015, all countries have case-based measles surveillance and 
report at least 2 non-measles cases per 100,000 population
Strategies:
 i.  Provide technical assistance on developing global, regional, and 
national VPD surveillance policies and guidelines, including 
quality standards. 
 ii.  Provide technical assistance on developing national capacity for 
VPD surveillance systems linked to VPD laboratory networks, 
including capacity to interpret and use information generated. 
 iii.  Conduct national and sub-national reviews of VPD surveillance 
systems.
3.  Increase the number of countries with information systems 
meeting the minimum quality criteria required to effectively 
monitor and manage immunization programs  
Key measure of success:  
By 2015, 75% of countries have published information system 
policies and guidelines pertaining to the immunization program
Strategies:
 i.  Provide technical assistance on developing global, regional, and 
national immunization program information system policies and 
guidelines, including quality standards.
 ii.  Build national and regional capacity to sustain, improve, and 
monitor immunization program information systems that 
will ensure high-quality data collection, data management, 
information exchange, and use of standard operating procedures.
 iii.  Develop tools and methods for tracking immunization program 
targets and performance and for validating performance (e.g., 
improved methods for vaccine coverage surveys).
 iv.  Provide technical assistance on monitoring and evaluating 
national immunization programs, to include linking VPD 




Increase the appropriate development, introduction, and use of 
new and underused vaccines (NUVs) (e.g., Hib, pneumococcal, 
rotavirus, HPV, MenA, HepB birth dose, rubella, JE vaccine, 
cholera, typhoid, influenza, malaria, yellow fever) to prevent 
diseases of global and regional public health importance  
(NVP Goal 5/Objective 5.3)
Objectives
1.  Increase the percentage of the global birth cohort that has 
access to NUVs as part of a national immunization schedule 
and, within 5 years of introduction, achieve the same 
vaccination coverage level for NUVs as for other vaccines  
given at the same age 
Key measures of success:  
By 2015, 45 GAVI-eligible countries have introduced PCV  
By 2015, 33 GAVI-eligible countries have introduced rotavirus 
vaccine 
Strategies:
 i.  Support national decision making on NUV introduction by 
providing technical assistance on evaluation of disease burden, 
surveillance capacity, economic analysis methods, program 
implications, and vaccine impact.
 ii.  Integrate the introduction of NUVs into each country’s 
comprehensive multiyear plan, and provide the technical 
assistance necessary for successfully incorporating NUVs into 
routine immunization programs; link routine immunization 
programs with disease-specific control programs. 
 iii.  Provide technical assistance to countries on assessing NUV 
effectiveness, impact on reducing childhood morbidity and 
mortality, and impact on immunization programs, and on 
evaluating barriers to achieving full coverage.
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2.  Increase the number of new vaccines, improved vaccines, 
and combination vaccines that are prequalified by WHO for 
use in national immunization programs
Key measure of success:  
By 2015, one cell-based influenza vaccine and one additional 
LAIV vaccine will be prequalified by WHO
Strategies: 
 i.  Support development of vaccine reference strains and candidate 
vaccines against diseases of public health importance, especially 
to aid in response to emerging infections. 
 ii.  Conduct studies on, and develop surveillance and laboratory 
capacity for, determining the disease and economic burden of 
targeted VPDs. 
 iii.  Conduct and support research to evaluate efficacy and 
effectiveness of new formulations, dosing schedules, and 
alternative routes of administration for available vaccines. 
 iv.  Develop laboratory methods and standards for evaluating 





Promote synergies between immunization programs and other 
public health interventions to strengthen health systems and 
contribute to decreased maternal and child mortality and 
morbidity (NVP Goal 5/Objective 5.2)
Objectives
1.  Increase the number of countries that have developed, 
implemented, and evaluated comprehensive national 
maternal and child health plans of action that appropriately 
integrate immunization with other priority health 
interventions 
Key measure of success:  
By 2012, at least three GHI countries integrate immunization 
services with at least one other priority health intervention 
Strategies:
 i.  Provide technical assistance on developing guidelines and 
standards for global and national plans of action for integrated 
disease control programs that address diarrhea, pneumonia, and 
other major causes of VPD-related mortality. 
 ii.  Provide technical assistance at the national and sub-national 
level on appropriately using routine childhood immunization 
programs as a platform for the delivery of other priority health 
services.
 iii.  Develop standardized methods and tools for monitoring and 
evaluating the efficiency, effectiveness, and impact of combined 
public health interventions.
 iv.  Contribute to the development and implementation of a research 
agenda to strengthen the scientific basis for integration of 
immunization with other priority health interventions.
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2.  Increase the number of countries that use immunization 
system capacity to provide information needed to make 
sound decisions on other priority health interventions 
Key measure of success:  
By 2012, at least two GHI countries integrate monitoring of 
immunization services with at least one other monitoring system 
for a priority health intervention 
Strategies:
 i.  Develop tools and methods for linking the monitoring of 
immunization program performance and vaccine delivery 
with monitoring of programs that deliver other priority health 
interventions.
 ii.  Provide technical assistance on creating and enhancing 
integrated VPD surveillance and laboratory systems as a part of 
comprehensive communicable disease surveillance capacity.
 iii.  Build national and sub-national capacity for data analysis and 
program management by linking epidemiology, outbreak control, 
and management training for immunization program staff and 
other public health decision makers.
 iv.  Contribute to the development and implementation of a research 
agenda to strengthen the scientific basis for integration of 





Build and strengthen partnerships that maximize coordination 
and synergy in meeting immunization goals (NVP Goal 5/
Objective 5.6)
Objectives
1.  Increase the capacity of global, regional, and national 
partnerships to effectively plan, coordinate, fund, and 
implement strategies for reaching global immunization 
goals
Key measures of success:  
By 2012, build and sustain the operation of a global partnership 
that has a concrete plan of action and champions the 
strengthening of routine immunization programs and achieving 
priority global immunization targets  
By 2012, develop a Meningitis Initiative partnership to ensure 
coordination, sufficient funding, and technical resources to 
implement MenA campaigns in all countries in the Africa 
meningitis belt by 2017 and to monitor the elimination of 
serogroup A meningitis epidemics
Strategies: 
 i.  Participate in and provide technical assistance at global, regional, 
and national forums on establishing global immunization goals, 
objectives, priorities, and policy.
 ii.  Support development and sustainability of external partnerships 
to reach key global immunization goals. 
 iii.  Provide appropriate economic analyses and program evaluations 
to determine financial resource requirements, identify funding 
gaps, and develop plans for meeting resource requirements and 
successfully implementing global immunization programs.
 iv.  Develop key communication messages and implement advocacy 
measures to gain political and financial support for meeting 
immunization objectives. 
 v.  Work with global partners to rapidly detect and respond to 
emerging infections and global VPD outbreaks, including 
securing and maintaining adequate stockpiles or strategic 
reserves of appropriate vaccines.
 vi.  Strengthen partnerships within the USG to support global 
immunization goals as part of a comprehensive plan for 
enhancing maternal and child health.
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